Published : Nov-2018
No. of Pages : 108
1.1 List of Tables
1.2 List of Figures
2 Atopic Dermatitis: Executive Summary
2.1 Atopic Dermatitis Market to Experience Strong Growth from 2017?2027
2.2 Late-Stage Pipeline Product Launches Will Result in New Players Establishing Themselves
2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period
2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the Atopic Dermatitis Pipeline
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods - Population
5.4.3 Forecast Assumptions and Methods - One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis
5.4.4 Forecast Assumptions and Methods - One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
5.4.5 Forecast Assumptions and Methods - One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
5.5 Epidemiological Forecast for Atopic Dermatitis (2017?2027)
5.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.3 Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis
5.5.4 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity
5.5.5 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.6 Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.7 Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis
5.5.8 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
7 Competitive Assessment
7.1 Overview
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Topical Treatments Without Side Effects
8.3 A Drug that Effectively Controls Patients' Pruritus
8.4 Addressing Heterogeneity in the Pathophysiology of Atopic Dermatitis
8.5 Improved Patient Compliance and Education
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 LEO Pharma
10.3.2 Pfizer
10.3.3 Regeneron
10.3.4 AbbVie
10.3.5 Dermira
10.3.6 Eli Lilly
10.3.7 Galderma
10.3.8 Incyte
10.4 Other Players
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - Key Opinion Leaders and Payers Interviewed for This Report
12.4.1 Key Opinion Leaders
12.4.2 Payers
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Reviewer
12.6.3 Therapy Area Director
12.6.4 Epidemiologist
12.6.5 Managing Epidemiologists
12.6.6 Global Director of Therapy Analysis and Epidemiology
12.6.7 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
1.1 List of Tables
Table 1: Atopic Dermatitis: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbid Conditions Associated with Atopic Dermatitis
Table 3: Treatment Guidelines for Atopic Dermatitis
Table 4: Country Profile - US
Table 5: Country Profile - 5EU
Table 6: Country Profile - Japan
Table 7: Leading Treatments for Atopic Dermatitis, 2017
Table 8: Comparison of Therapeutic Classes in the Development for Atopic Dermatitis, 2017-2027
Table 9: LEO Pharma's Atopic Dermatitis Portfolio Assessment, 2018
Table 10: Pfizer's Atopic Dermatitis Portfolio Assessment, 2018
Table 11: Regeneron's Atopic Dermatitis Portfolio Assessment, 2018
Table 12: AbbVie's Atopic Dermatitis Portfolio Assessment, 2018
Table 13: Dermira's Atopic Dermatitis Portfolio Assessment, 2018
Table 14: Eli Lilly's Atopic Dermatitis Portfolio Assessment, 2018
Table 15: Galderma's Atopic Dermatitis Portfolio Assessment, 2018
Table 16: Incyte's Disease Portfolio Assessment, 2018
Table 17: Atopic Dermatitis Market - Global Drivers and Barriers, 2017-2027
Table 18: Key Events Impacting Sales for Atopic Dermatitis in the US, 2017-2027
Table 19: Atopic Dermatitis Market - Drivers and Barriers in the US, 2017-2027
Table 20: Key Events Impacting Sales for Atopic Dermatitis in the 5EU, 2017-2027
Table 21: Atopic Dermatitis Market - Drivers and Barriers in the 5EU, 2017-2027
Table 22: Key Events Impacting Sales for Atopic Dermatitis in Japan, 2017-2027
Table 23: Atopic Dermatitis Market - Global Drivers and Barriers in Japan, 2017-2027
Table 24: Key Projected Launch Dates for Atopic Dermatitis
Table 25: Key Historical and Projected Patent Expiry Dates for Atopic Dermatitis
Table 26: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for Atopic Dermatitis in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period
Figure 4: Major Drug Targets for Atopic Dermatitis Treatment
Figure 5: 7MM, Age-Standardized One-Year Total Prevalence of Atopic Dermatitis (%), Both Sexes, All Ages, 2017
Figure 6: 7MM, Sources Used and Not Used to Forecast the One-Year Total and Diagnosed Prevalent Cases of Atopic Dermatitis
Figure 7: 7MM, Sources Used to Forecast the One-Year Total Prevalence by Severity of Atopic Dermatitis
Figure 8: 7MM, Sources Used to Forecast the One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis
Figure 9: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 10: 7MM, Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 11: 7MM, Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017
Figure 12: 7MM, One-Year Total Prevalent Cases of Atopic Dermatitis by Severity, Both Sexes, All Ages, N, 2017
Figure 13: 7MM, One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 14: 7MM, Age-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 15: 7MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic Dermatitis, All Ages, N, 2017
Figure 16: 7MM, One-Year Diagnosed Prevalent Cases by Severity of Atopic Dermatitis, Both Sexes, All Ages, N, 2017
Figure 17: Flowchart of the Diagnosis and Management of Atopic Dermatitis
Figure 18: Unmet Needs and Opportunities in Atopic Dermatitis
Figure 19: Overview of the Development Pipeline in Atopic Dermatitis
Figure 20: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Atopic Dermatitis in the 7MM During the Forecast Period
Figure 21: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Atopic Dermatitis During the Forecast Period
Figure 22: Analysis of the Company Portfolio Gap in Atopic Dermatitis During the Forecast Period
Figure 23: Global (7MM) Sales Forecast for Atopic Dermatitis by Country in 2017 and 2027
Figure 24: Sales Forecast for Atopic Dermatitis by Class in the US in 2017 and 2027
Figure 25: Sales Forecast for Atopic Dermatitis in the 5EU by Class in 2017 and 2027
Figure 26: Sales Forecast for Atopic Dermatitis by Class in Japan in 2017 and 2027
